1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Cosmax BTI Inc.

Cosmax BTI Inc.

KKRX:044820
22,350.00
KRW
0.00
(0.00%)
8,221.45EPS
2.57P/E
163.87BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14,084.78
17,295.75
20,904.56
27,933.52
31,192.98
45,841.99
49,297.55
55,055.25
60,274.67
64,616.87
65,763.56
62,541.06
67,506.27
80,724.85
Basic EPS, GAAP
4,820.71
1,725
837
1,607
402
994
42
-674
1,479
-683.21
948
1,722
3,056
6,675.29
Free Cash Flow per Basic Share
-4,643.81
-5,028.53
-8,211.11
-7,200.55
-6,850.85
-5,707.63
-3,501.41
2,986.31
-977.2
1,697.27
216.47
242.03
260.68
1,481.69
Dividend per Share
799.17
565.64
239.77
130.04
199.91
99.98
289.87
250.16
233.64
260
- -
349.96
449.86
779.98
Book Value per Share
20,846.05
27,237.21
29,218.8
30,362.95
30,218.16
31,281.21
32,216.68
30,463.45
32,252.08
31,501.59
24,262.78
26,341.22
28,837.23
33,929.37
Tangible Book Value per Share
18,849.48
25,230.58
27,190.94
27,793.91
27,583.58
27,903.78
28,835.5
27,706.96
29,842.06
29,183.01
21,878.28
23,726.32
26,109.99
31,240.97
Basic Weighted Avg Shares
5
8
10
10
10
10
10
10
10
10
10
10
10
10
Sales/Revenue/Turnover
64,068
135,907
199,869
266,925
298,287
438,275
468,353
525,904
575,998
617,404
628,597
597,630
645,206
771,332
Operating Margin (%)
4.63
5.29
5.63
7.55
3.4
5.51
-1.56
0.23
2.07
0.55
3.22
2.81
4.18
5.6
Depreciation Expense
8,065
5,679
7,008
10,049
13,922
20,414
25,504
26,861
28,392
28,402
26,325
28,009
27,575
26,248
Net Income, GAAP
21,928
13,555
8,003
15,356
3,844
9,503
399
-6,438
14,134
-6,528
9,061
16,455
29,208
63,783
Effective Tax Rate (%)
1.25
19.29
13.26
13.9
32.37
33.59
- -
- -
78.76
- -
77
56.64
24.91
- -
Profit Margin (%)
34.23
9.97
4
5.75
1.29
2.17
0.09
-1.22
2.45
-1.06
1.44
2.75
4.53
8.27
Working Capital
32,497
-15,481
-10,539
-21,597
-149,180
-202,760
-202,145
-177,761
-148,854
-148,629
-273,495
-288,491
-278,245
-222,921
LT Debt
65,294
39,087
86,682
153,980
89,807
91,384
76,720
97,697
155,802
128,360
21,328
27,865
16,361
35,194
Total Equity
102,317
275,556
325,412
346,648
343,678
359,848
355,990
332,235
341,897
325,762
252,396
281,230
295,687
366,804
Return on Invested Capital (%)
1.5
2
2.32
3.28
1.14
2.34
- -
- -
0.32
- -
0.62
0.97
2.53
- -
Return on Capital (%)
10.3
4.5
2.07
2.03
1.22
2.14
- -
- -
3.38
- -
2.83
4.75
7.31
- -
Return on Common Equity (%)
25.48
7.63
2.97
5.39
1.33
3.23
0.13
-2.15
4.72
-2.14
3.4
6.81
11.08
22.45

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
497,586
475,271
470,954
LT Borrowings
15,138
33,561
33,006
LT Finance Leases
1,222
2,355
2,188
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
129,659
150,011
163,865

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
349,893
380,059
422,889
Cash, Cash Equivalents & STI
107,183
78,084
83,498
Accounts Receivable, Net
117,432
159,914
163,907
Inventories
80,187
88,414
101,226
Total Current Liabilities
628,137
630,776
645,811
Payables & Accruals
- -
- -
- -
ST Debt
497,586
475,271
470,954
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.51%
-1.55%
5.14%
Free Cash Flow
-73.28%
-94.83%
7.73%
Net Income, GAAP
-219.06%
-109.09%
77.5%
Sales/Revenue/Turnover
13.29%
4.31%
7.96%
Total Cash Common Dividend
- -
- -
28.57%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
140,241
158,969
151,885
146,535
597,630
2025
154,316
163,726
153,467
173,697
645,206
2026
205,191
238,977
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
106
852
212
551.43
1,722
2025
68
854
-201.17
2,334.78
3,056
2026
1,477.55
3,064
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
349.07
- -
- -
- -
349.96
2025
447.91
- -
- -
- -
449.86
2026
780
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Byung-Man Lee
Full Time Employees
341
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building F, Pangyo Inno Valley Seongnam-si GY South Korea
IPO Date
Nov 13, 2006
Website
cosmaxbti.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Cosmax BTI, Inc. engages in the research, development, production, and sale of cosmetics, health functional foods, pharmaceuticals, and special containers primarily in South Korea with exports to international markets. Founded in 1984 and headquartered in Seongnam-si, South Korea, the company offers an extensive range of cosmetics including skincare, masks, cleansing, hair care, bath and body, sun care, makeup, cushions, eye and lip makeup, nail, and fragrance products; baby and child cosmetics; Korean herbal cosmetics; and cosmeceuticals; alongside health supplements in gels, capsules, and powders; medical devices; and specialized packaging solutions. It operates through segments such as dietary supplements, functional cosmetics packaging, logistics services, equipment services, and overseas marketing, serving large corporate clients as an original design manufacturer in the household and personal products industry. In recent developments, Cosmax BTI reports steady revenue growth with 2024 sales reaching 597.63 billion KRW despite a slight decline from the prior year, alongside net income of 16.46 billion KRW; for the first nine months of 2025, sales total 48.58 billion KRW and net income stands at 6.90 billion KRW. The company maintains strategic focus on global expansion and innovation, including ongoing research collaborations such as with the National University of Singapore on microbiome technologies for new materials like natural emulsification systems and anti-aging beneficial bacteria. Under leadership including CEO Joon-Bae Kim and Chairperson Kyung-Soo Lee, Cosmax BTI benefits from affiliation with the broader Cosmax group, positioning it to capitalize on K-beauty demand while enhancing production and R&D capabilities.